AbbVie escaped the wrath of the FTC in a pay-for-delay suit over AndroGel generics, as a federal judge who previously threw out antitrust claims against the company rejected the agency's attempts to reconsider its case.
Teva has upped its Mylan stake yet again--this time, passing a critical threshold that could help it pose a legal challenge to its generics rival.
Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.
Teva Pharmaceutical Industries said it has completed its $3.2 billion acquisition of Auspex Pharmaceuticals, a U.S.-based biopharmaceutical company specializing in development of nervous-system therapies.
Yesterday, Teva formally tied off its collaboration with Seattle-based OncoGenex after handing over a $23 million payment as it exited a partnership to develop the biotech's late-stage cancer drug custirsen. Today, OncoGenex took the next step in its survival plan, trimming down the size and length of an ongoing trial as it reorganizes in the face of a major setback.
An Israeli court ordered Teva Pharmaceutical to not only return the Copaxone (glatiramer acetate) multiple sclerosis drug it licensed from Proneuron Biotechnologies but also return 14 indications it received for other nervous system drugs. Oh, and pay Proneuron the equivalent of $128,666 as well.
Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.
Teva Pharmaceutical Industries and Barr Pharmaceuticals agreed to pay the largest settlement ever for a pharmaceutical "pay-for-delay" deal, $512 million. Fellow defendants Ranbaxy Laboratories and Mylan did not agree to the settlement.
Israel's Teva Pharmaceutical Industries is reported to be considering a $34 billion takeover of British-based Mylan. But if it indeed is, the takeover would have to be a hostile one given Mylan's strongly worded response to the reports.
Pharma puts so much emphasis on top line that drugmakers give scant consideration to what their supply chains are costing them. But a new report suggests that making a supply chain more efficient is not only going to save costs, but it will also help drive greater sales.